GlassScriptPhysician profile
Lori M Kolb
NPI 1467929729
$900.21
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $900.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $112.88 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $85.94 | 2021 | |
| Celgene Corporation | $79.30 | 2021 | |
| Ucb, INC. | $60.84 | 2021 | |
| Amgen INC. | $57.82 | 2021 | |
| Novartis Pharmaceuticals Corporation | $55.59 | 2021 | |
| Csl Behring | $47.73 | 2021 | |
| Eisai INC. | $40.71 | 2021 | |
| Neurelis, INC. | $39.55 | 2021 | |
| Supernus Pharmaceuticals, INC. | $39.42 | 2021 | |
| Upsher-Smith Laboratories LLC | $39.27 | 2021 | |
| Genzyme Corporation | $39.14 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $36.53 | 2021 | |
| Lilly USA, LLC | $24.67 | 2021 | |
| Alexion Pharmaceuticals, INC. | $24.61 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $24.31 | 2021 | |
| Amneal Pharmaceuticals LLC | $24.03 | 2021 | |
| Acadia Pharmaceuticals INC | $21.01 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.47 | 2021 | |
| Neurocrine Biosciences, INC. | $15.98 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.41 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Kolb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.